Overview

Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study

Status:
Not yet recruiting
Trial end date:
2028-03-02
Target enrollment:
Participant gender:
Summary
This phase II trial compares the effect of short course radiotherapy (RT) to standard course RT for the treatment of patients diagnosed with glioblastoma (GBM). The researchers want to learn whether the shorter course treatment is non-inferior (not worse than the standard of care), for patients with GBM. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Short course radiotherapy delivers higher doses of radiation over a shorter period of time and may kill more tumor cells and have fewer side effects.
Phase:
Phase 2
Details
Lead Sponsor:
Mayo Clinic
Treatments:
Fluorides
Levodopa
Temozolomide